Associated Papers
Somatic mutation and selection at population scale.
Lawson ARJ et al.
Nature, 2025
41062696 (PubMed )
Supplement: 41586_2025_9584_MOESM6_ESM.xlsx › sitednds_oral
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms.
Sperling AS et al.
Blood, 2022
35512188 (PubMed )
Supplement: BLOOD_BLD-2021-014956-mmc1.pdf
PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation.
Khadka P et al.
Nature Communications, 2022
35105861 (PubMed )
Supplement: 41467_2022_28198_MOESM5_ESM.xls › Sheet1
Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib.
Wang Z et al.
Molecular Cancer Research : Mcr, 2020
PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma.
Fons NR et al.
Nature Communications, 2019
Diagnosis of Li-Fraumeni Syndrome: Differentiating TP53 germline mutations from clonal hematopoiesis: Results of the observational AGO-TR1 trial.
Weber-Lassalle K et al.
Human Mutation, 2018
PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy.
Hsu JI et al.
Cell Stem Cell, 2018
30388424 (PubMed )
Supplement: mmc2.pdf
Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential.
Wong TN et al.
Nature Communications, 2018
29386642 (PubMed )
Supplement: 41467_2018_2858_MOESM5_ESM.xlsx › Sheet1
Inhibition of C-terminal truncated PPM1D enhances the effect of doxorubicin on cell viability in human colorectal carcinoma cell line.
Kozakai Y et al.
Bioorganic & Medicinal Chemistry Letters, 2014
Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas.
Zhang L et al.
Nature Genetics, 2014
Select a paper to view details